Structure of Buserelin CAS# 68630-75-1

Iden­ti­fi­ca­tion

CAS Number

68630-75-1

Name

Busere­lin

Syn­onyms

5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-(2-methyl-2-propanyl)-D-seryl-L-leucyl-L-arginyl-N-ethyl-L-prolinamidacetat (1:1) [Ger­man] [ACD/IUPAC Name]
5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-(2-methyl-2-propanyl)-D-seryl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (1:1) [ACD/IUPAC Name]
5-oxo-L-pro­­lyl-L-his­tidyl-L-tryp­­to­­phyl-L-seryl-L-tyro­­syl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-N-eth­yl-L-pro­li­­namide acetate (1:1)
68630-75-1 [RN]
Acide acé­tique – 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-séryl-L-tyrosyl-O-(2-méthyl-2-propanyl)-D-séryl-L-leucyl-L-arginyl-N-éthyl-L-prolinamide (1:1) [French] [ACD/IUPAC Name]
Busere­lin acetate [JAN] [USAN]
Busere­lin monoac­etate
HOE 766MP {Acetate}
L-Pro­li­­namide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-(1,1-dimethylethyl)-D-seryl-L-leucyl-L-arginyl-N-ethyl-, acetate (1:1) [ACD/​Index Name]
(Des-Gly10,D-Ser(tBu)6,Pro-NHEt9)-LHRH
(S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6-((1H-indol-3-yl)methyl)-15-(tert-butoxymethyl)-21-(3-((diaminomethylene)amino)propyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-ethylpyrrolidine-2-carboxamide acetate
[68630-75-1]
1-9-Luteiniz­ing hor­­mone-releas­ing fac­tor (swine), 6-[O-(1,1- dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-, monoac­etate (salt)
261-061-9 [EINECS]
57982-77-1 [RN]
5-Oxo-L-pro­­lyl-L-his­tidyl-L-tryp­­to­­phyl-L-seryl-L-tyro­­syl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-N-eth­yl-L-pro­li­­namide monoac­etate (salt)
Busere­lin acetate (JAN/USAN) [JAN] [USAN]
HOE 766 MP
Hoe-766 MP
MFCD00870371 [MDL num­ber]
MFCD01716229
Supre­cur [Trade name]
Supref­act

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC­NC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O

Std­InChI

InChI=1S/C60H86N16O13.C2H4O2/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40;1-2(3)4/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65);1H3,(H,3,4)/t40-,41-,42-,43-,44-,45-,46-,47+,48-;/m0./s1

Std­InChIKey

PYMD­ED­HDQYL­BRT-DRI­H­­CAF­S­SA-N

Mol­e­c­u­lar Formula

C62H90N16O15

Mol­e­c­u­lar Weight

1299.47

MDL Number

MFCD00941414

Prop­er­ties

Appear­ance

White or slight­ly yel­low­ish powder

Safe­ty Data

Sym­bol

exclamation-mark-jpgexclamation-mark-jpgGHS07,GHS08

Sig­nal Word


Dan­ger

Haz­ard statements

H302H360

Pre­cau­tion­ary Statements

P201P301 + P312 + P330P308P313

Per­son­al Pro­tec­tive Equipment

Eye­shields, Faceshields, Gloves, res­pi­ra­tor car­tridge type N100 (US), type P1 (EN143) res­pi­ra­tor fil­ter, type P3 (EN 143) res­pi­ra­tor cartridges

RIDADR 

NONH for all modes of transport

WGK Germany

3

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Busere­lin CAS 68630-75-1

Iden­ti­fi­ca­tion Methods

HPLC

Assay

95%~102%

Spe­cif­ic Opti­cal Rotation

-49.0 ~ -58.0°[a] 20 D (c=1, water)

Spe­cif­ic Absorbance(By anhy­drous, acetic acid-free)

49~56(278nm)

Water

≤4.0%

Amino Acid Composition

Arg0.9 ~ 1.1
Leu0.9 ~ 1.1
Tyr0.9 ~ 1.1
Glu0.9 ~ 1.1
Pro0.8 ~ 1.2
His0.9 ~ 1.1
Ser1.4 ~ 2.0
TrpDetect­ed

Relat­ed Sub­stance (By HPLC)

Sin­gle Impurity

≤1.0%

Total Impu­ri­ties

≤5.0%

Acetate Con­tent (By HPLC)

3~7%

Bac­te­r­i­al Endotoxins

≤55.5 IU/​mg

Shelf Life

2 years

Stor­age

Store at 2~8℃, sealed and away from light.

Known Appli­ca­tion

It is often used to treat prostate can­cer, breast can­cer, endometrio­sis, uter­ine fibroids and oth­er dis­eases. The clin­i­cal dosage forms are injec­tions and nasal sprays.

This prod­uct is devel­oped by our R&D com­pa­ny Apnoke Sci­en­tif­ic Ltd (http://​www​.wat​son​noke​.com/), and here is the cor­re­spond­ing linkhttp://​www​.apnoke​.com/​b​u​s​e​r​e​l​i​n​a​c​e​t​a​t​e​-​c​a​s​-​6​8​6​3​0​-​7​5​-1/

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you short­ly (Please change screen to hor­i­zon­tal for com­plete brows­ing if you are check­ing Wat­son on your mobile phone). 

























    Please prove you are human by select­ing the plane.